Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension
Authors:
- 1 January 2006
- journal article
- research article
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 29 (12) , 997-1005
Abstract
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japanese men and women with a mean sitting diastolic blood pressure of 95–110 mmHg were randomized to receive once-daily double-blind treatment for 8 weeks with aliskiren 75, 150 or 300 mg or placebo. Aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (pvs. placebo for each dose) and mean sitting systolic blood pressure (pvs. placebo for each dose). The placebo-corrected reductions in mean sitting systolic/diastolic blood pressure were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg in the aliskiren 75, 150 and 300 mg groups, respectively. After 8 weeks' treatment, 27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo and aliskiren 75, 150 and 300 mg groups, respectively, achieved a successful treatment response (diastolic blood pressure pvs. placebo for each dose). Aliskiren treatment was well tolerated, with the incidence of adverse events reported in the active treatment groups (53–55%) being similar to that in the placebo group (50%). This study, which is the first to assess the antihypertensive efficacy and safety of aliskiren in Japanese patients with hypertension, demonstrates that the once-daily oral renin inhibitor aliskiren provides significant, dose-dependent reductions in blood pressure with placebo-like tolerability.Keywords
This publication has 34 references indexed in Scilit:
- Current Status of Antihypertensive Prescription and Associated Blood Pressure Control in JapanHypertension Research, 2006
- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialThe Lancet, 2005
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Renin, Angiotensin, Sodium and Organ DamageHypertension Research, 2003
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- Blood Pressure Control Assessed by Home, Ambulatory and Conventional Blood Pressure Measurements in the Japanese General Population: the Ohasama StudyHypertension Research, 2002
- Tissue Angiotensin and Pathobiology of Vascular DiseaseHypertension, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- The renin-angiotensin-aldosterone system: a specific target for hypertension managementAmerican Journal of Hypertension, 1999
- Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor.Hypertension, 1994